Indivior
INDV
$36.19
+1.86%
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on developing, manufacturing, and commercializing buprenorphine-based prescription treatments for opioid use disorder (OUD), which it frames as a chronic but treatable brain disease. Its flagship products include Sublocade, a long-acting monthly injectable, and Suboxone, a sublingual film combining buprenorphine and naloxone, positioning the firm as a pure-play leader in a niche but medically critical corner of the specialty and generic drug industry. The current investor narrative is dominated by the proposed merger with Supernus Pharmaceuticals, which management has framed as capable of unlocking roughly $125 million in annual synergies, even as an earnings miss and integration/execution risks temper enthusiasm. At the same time, the stock's sharp one-year outperformance against the broader market reflects growing conviction in the long-acting injectable franchise and the durability of OUD treatment demand, while recent weakness suggests investors are reassessing deal timing and near-term cash flow dynamics.…
INDV
Indivior
$36.19
Related headlines
Investment Opinion: Should I buy INDV Today?
Rating: Hold. The core thesis is that INDV offers a compelling value proposition on forward earnings (7.14x PE) with 40.5% upside to the $49 analyst average target, but near-term cash flow deficits and merger execution risks warrant caution until there is clearer evidence of synergy realization and working capital normalization. The consensus rating is effectively bullish (four Buy/Overweight ratings, no downgrades), yet the stock's recent underperformance suggests the market is pricing in skepticism.
Supporting evidence includes: 1) Revenue growth of 19.17% year over year in Q1 2026, with a long-acting injectable franchise driving demand; 2) Exceptional profitability with gross margin of 87.4% and operating margin of 43.2%, well above typical specialty pharma levels; 3) A forward PE of 7.14x versus a trailing PE of 21.36x, implying significant earnings growth that is not yet reflected in the price; 4) Analyst targets ranging from $43 to $53, with an average of $49, implying 23–52% upside; and 5) The potential for $125 million in annual synergies from the Supernus merger. However, these positives are offset by negative free cash flow of -$184.6 million and a current ratio of 0.71.
The biggest risks that could invalidate the thesis are: 1) Failure to achieve the $5.41 forward EPS, which would make the low multiple justified; 2) A liquidity crunch if cash burn continues, potentially requiring dilutive financing; and 3) Merger integration missteps or regulatory hurdles. The rating would upgrade to Buy if free cash flow turns positive and the merger closes on favorable terms, or if the stock pulls back to the low $30s while fundamentals remain intact. It would downgrade to Sell if forward EPS estimates are cut below $4.00 or if the current ratio falls below 0.5. Relative to its own history, the stock is near the low end of its valuation band (PS of 3.62x vs. 12.05x in Q1 2026), suggesting it is undervalued if execution improves, but fairly valued if cash flow issues persist.
Sign up to view all
INDV 12-Month Price Forecast
INDV presents a high-risk, high-reward opportunity with a deeply discounted forward valuation that hinges on merger execution and cash flow improvement. The bull case is supported by strong revenue growth, elite margins, and unanimous analyst optimism, but the bear case is equally compelling given negative free cash flow and thin liquidity. The stock's recent 10.66% one-month decline and underperformance versus SPY suggest the market is pricing in deal risk. I would upgrade to bullish if free cash flow turns positive and the merger closes, or downgrade to bearish if forward EPS estimates are cut or liquidity deteriorates further. The risk/reward is balanced at current levels, favoring a Hold until clearer catalysts emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Indivior's 12-month outlook, with a consensus price target around $49.00 and implied upside of +35.4% versus the current price.
Average Target
$49.00
0 analysts
Implied Upside
+35.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$43 - $53
Analyst target range
Coverage is thin but uniformly constructive. Four analysts cover INDV, and the institutional ratings history shows a consistent bullish tilt with no downgrades — HC Wainwright reiterated Buy in January 2026, Piper Sandler maintained Overweight in October 2025, and Craig-Hallum reiterated Buy in August 2025. The consensus average target price is $49.00, which implies roughly 40.5% upside from the current $34.88, with an estimated average EPS of $5.41 and average revenue of $1.55 billion. The recommendation field is listed as "none," but the underlying actions are clearly bullish, so the consensus leans strongly positive.
The target range runs from a low of $43.00 to a high of $53.00, a spread of about 23% around the average — relatively tight for a small-cap specialty pharma, which signals reasonably strong conviction rather than wide disagreement. The high target of $53.00 implies roughly 52% upside and likely assumes successful merger integration, realization of the $125 million in synergies, and multiple expansion on the $5.41 forward EPS. The low target of $43.00 still implies about 23% upside, suggesting even the bear case does not price in a broken thesis, but it likely assumes slower synergy capture, margin pressure, or deal-related execution risk. With only four analysts and no recent downgrades, the signal is positive but should be weighted cautiously given limited coverage, which can amplify volatility and reduce price-discovery efficiency.
Bulls vs Bears: INDV Investment Factors
The bull case rests on a deeply discounted forward PE of 7.14x, 19.2% revenue growth, elite margins (87.4% gross, 43.2% operating), and 40.5% analyst upside to a $49 target. The bear case centers on negative free cash flow of -$184.6 million, a current ratio of 0.71, recent momentum breakdown (-10.66% in one month), and merger execution risk. Currently, the bear evidence carries more weight because cash burn and liquidity concerns are immediate and quantifiable, while the bull case depends on forward earnings that have yet to materialize. The single most important tension is whether the $5.41 forward EPS can be achieved—if it does, the stock is dramatically undervalued; if not, the low multiple is justified. Resolution likely hinges on merger integration and working capital normalization over the next two to three quarters.
Bullish
- Forward PE of 7.14x is deeply discounted: INDV trades at a forward PE of just 7.14x versus a trailing PE of 21.36x, implying the market expects EPS to roughly triple to the $5.41 consensus estimate. This is well below the mid-teens to low-20s multiples typical of profitable specialty pharma peers, creating a valuation gap if earnings materialize.
- Revenue growth accelerating at 19.2% YoY: Q1 2026 revenue of $317 million rose 19.17% year over year, driven by the long-acting injectable franchise. The sequential path from $302M (Q2 2025) to $358M (Q4 2025) shows underlying demand strength despite a seasonal Q1 dip.
- Exceptional gross and operating margins: Q1 2026 gross margin reached 87.4% and operating margin 43.2%, with net margin at 28.1%. These are elite profitability metrics for specialty pharma, reflecting the high-value, concentrated buprenorphine portfolio.
- Analyst targets imply 40.5% upside: The consensus average target price of $49.00 implies 40.5% upside from $34.88, with a tight range of $43–$53. All four covering analysts have reiterated Buy or Overweight ratings with no downgrades, signaling strong conviction.
Bearish
- Negative free cash flow of -$184.6M TTM: Trailing free cash flow is deeply negative at -$184.6 million, and Q1 2026 operating cash flow was -$9 million with FCF of -$29 million. A $163 million working capital outflow and $151 million debt repayment drained cash to $175 million from $195 million, raising financing risk.
- Thin liquidity with current ratio of 0.71: The current ratio of 0.71 and quick ratio of 0.66 indicate that current liabilities exceed current assets, leaving little short-term financial cushion. This is a red flag for a company with negative book value and ongoing cash consumption.
- Recent momentum breakdown and underperformance: INDV is down 10.66% over the past month and 8.93% over three months, underperforming SPY by 9.70 and 10.93 percentage points respectively. The stock sits at $34.88, only 61% of its 52-week range, signaling fading momentum.
- Merger execution and integration risks: The Supernus merger introduces significant execution risk, including potential delays, integration challenges, and an earnings miss that has already tempered enthusiasm. Failure to realize the $125 million in synergies could trigger a sharp de-rating.
INDV Technical Analysis
INDV is in a broad recovery uptrend that has cooled materially in recent months. The stock is up 52.38% over the past year, yet sits at $34.88, which is only about 61% of its 52-week range (low of $22.30, high of $42.81) — meaning it has given back a meaningful portion of its earlier advance and is no longer near its highs. That positioning implies the momentum trade has faded and the stock is now in a digestion phase rather than a fresh breakout, with the 52-week high of $42.81 acting as the key overhead reference.
Short-term momentum has clearly decelerated and is diverging from the longer-term trend. The stock is down 10.66% over the past month and 8.93% over three months, versus a 19.04% gain over six months and a 52.38% gain over one year, so the recent pullback is a genuine loss of momentum rather than a mere pause. Relative strength confirms the underperformance: INDV trails SPY by 9.70 percentage points over one month and 10.93 points over three months, even though it leads by 37.37 points over a year. With the stock down 2.27% on the latest session on volume of roughly 4.68 million shares, the near-term tape remains soft and the burden of proof is on buyers to stabilize the price.
Key technical levels are well defined. Support sits near the 52-week low of $22.30, with the more immediate battleground around the recent $34–$35 congestion zone; a decisive breakdown below that area would risk a retest of the lows and signal that the merger-related optimism is unwinding. Resistance is anchored at the 52-week high of $42.81, and a breakout above it would likely require either deal clarity or a fundamental re-rating. With a beta of 1.113, INDV is only modestly more volatile than the market — about 11% more — so position sizing should account for meaningful single-name event risk (the merger) rather than extreme market beta, while the 21.37% max drawdown shows the stock can fall hard when sentiment turns.
Beta
1.11
1.11x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$23-$43
Price range past year
Annual Return
+55.5%
Cumulative gain past year
| Period | INDV Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +1.0% |
| 3m | -12.7% | +5.5% |
| 6m | +20.8% | +19.9% |
| 1y | +55.5% | +16.0% |
| ytd | +1.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INDV Fundamental Analysis
Revenue is growing at a healthy clip, though the trajectory is uneven. The most recent quarter (Q1 2026, ended 2026-03-31) delivered revenue of $317.0 million, up 19.17% year over year, and the sequential path from $302 million (Q2 2025) to $314 million (Q3 2025) to $358 million (Q4 2025) to $317 million (Q1 2026) shows a seasonal dip after a strong year-end. The company operates as a single reportable segment at $317 million, so growth is driven by the core buprenorphine franchise rather than diversified business lines. The key question for the investment case is whether the long-acting injectable portfolio can sustain double-digit growth and offset the maturity of legacy film products, and the 19% YoY print supports that thesis even as the quarterly cadence remains lumpy.
Profitability is strong at the operating line and improving. Q1 2026 net income was $89.0 million on a 28.1% net margin, with gross margin of 87.4% and operating margin of 43.2% — exceptionally high for a specialty pharma, reflecting the economics of a concentrated, high-value product portfolio. The multi-quarter trend is constructive: net income moved from $18 million (Q2 2025) to $42 million (Q3 2025) to $102 million (Q4 2025) to $89 million (Q1 2026), and gross margin expanded from 80.3% in Q3 2025 to 87.4% in Q1 2026. The main caveat is that Q4 2025 benefited from a negative tax expense of $21 million, flattering that quarter's bottom line, so the underlying earnings power is somewhat less smooth than the headline numbers suggest.
Balance sheet and cash flow are the weak spot and the crux of the risk case. The current ratio is 0.71 and the quick ratio is 0.66, indicating thin short-term liquidity, while the debt-to-equity ratio of -3.58 and negative book value (P/B of -45.77) reflect an accumulated deficit that makes traditional leverage metrics hard to interpret. Free cash flow is negative on a trailing basis at -$184.6 million, and Q1 2026 operating cash flow was -$9 million with FCF of -$29 million, driven by a $163 million working capital outflow and $151 million of debt repayment; cash fell to $175 million from $195 million. ROE is -2.14 (distorted by negative equity) while ROA is a healthy 26.4%, so the business generates returns on assets but is currently consuming cash — meaning execution on the merger and working capital normalization are essential to avoid dependence on external financing.
Quarterly Revenue
$316999999.0B
2026-03
Revenue YoY Growth
+19.2%
YoY Comparison
Gross Margin
87.4%
Latest Quarter
Free Cash Flow
$-184619260.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INDV Overvalued?
Because net income is positive ($89 million in Q1 2026), the PE ratio is the appropriate primary metric. INDV trades at a trailing PE of 21.36x and a forward PE of just 7.14x, an unusually wide gap that implies the market expects earnings to roughly triple — consistent with analyst EPS estimates of $5.41 versus trailing EPS of about $0.05. The PS ratio of 3.62x and EV/Sales of 3.38x provide a cross-check, and the EV/EBITDA of 15.27x is moderate for a specialty pharma with 43% operating margins.
Relative to the broader specialty and generic drug industry, INDV screens as a value proposition on forward earnings. A forward PE of 7.14x is well below the mid-teens to low-20s multiples typical of profitable specialty pharma peers, and the 3.62x PS ratio is undemanding against a business with 80.1% gross margin and 16.9% net margin. The discount appears partly justified by the negative free cash flow, thin liquidity (current ratio 0.71), and merger-related uncertainty, but if the $5.41 forward EPS materializes, the stock is priced for substantial skepticism. The PEG ratio of 0.002 is distorted by near-zero trailing earnings and should not be relied upon.
On its own history, INDV's valuation has compressed dramatically. The trailing PE was 10.73x in Q1 2026 and 10.94x in Q4 2025, versus 17.73x in Q3 2025 and 26.32x in Q2 2025, while the PS ratio fell from 12.05x in Q1 2026 to 3.62x currently — a sharp de-rating. That places the stock near the low end of its recent valuation band, which can signal either a genuine value opportunity or the market pricing in fundamental deterioration and deal risk. The forward PE of 7.14x versus the trailing 21.36x is the single most important valuation signal: the market is only willing to pay a low multiple on the earnings it expects, implying limited tolerance for execution missteps.
PE
21.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute. INDV generated negative trailing free cash flow of -$184.6 million, with Q1 2026 operating cash flow of -$9 million and FCF of -$29 million, driven by a $163 million working capital outflow and $151 million debt repayment. The current ratio of 0.71 and quick ratio of 0.66 indicate that current liabilities exceed current assets, leaving minimal liquidity buffer. Additionally, revenue is concentrated in a single reportable segment—buprenorphine-based OUD treatments—with Q1 2026 revenue of $317 million, so any competitive or regulatory setback to Sublocade or Suboxone would directly hit the top line. The negative book value (P/B of -45.77) and debt-to-equity of -3.58 further complicate the capital structure and could limit access to external financing if cash burn persists.
Market and competitive risks are meaningful. INDV trades at a forward PE of 7.14x, which is a steep discount to specialty pharma peers, but this discount could persist or widen if the market doubts the $5.41 EPS estimate. The stock's beta of 1.113 means it is about 11% more volatile than the market, and its 21.37% max drawdown shows it can fall hard when sentiment turns. Recent news highlights that the Supernus merger could unlock $125 million in synergies but also carries execution risks and an earnings miss, which has already contributed to a 10.66% one-month decline and 9.70 percentage point underperformance versus SPY. Competitive pressures in the OUD space, including generic erosion and new entrants, could pressure pricing and margins.
The worst-case scenario involves a failed or delayed merger, continued cash burn, and a downward revision of forward EPS estimates. In that scenario, the stock could retest its 52-week low of $22.30, representing a 36.1% decline from the current price of $34.88. Even the analyst low target of $43.00 implies upside, but that assumes deal completion and synergy realization; if those assumptions fail, the stock could trade below $30. A more severe outcome—such as a liquidity crisis requiring dilutive financing—could push the stock toward the low $20s, a loss of 35–40% from current levels. Investors should size positions accordingly, given the binary nature of the merger outcome.
FAQ
The most severe risk is liquidity: a current ratio of 0.71 and negative free cash flow of -$184.6 million could force dilutive financing if cash burn continues. Second is merger execution risk—failure to realize the $125 million in synergies or a deal termination could send the stock toward its 52-week low of $22.30. Third is competitive pressure in the OUD space, where generic erosion could pressure Sublocade and Suboxone pricing. Fourth is valuation risk: the forward PE of 7.14x leaves little room for error, and any EPS miss could trigger a sharp de-rating. These risks are ranked from most to least immediate, with liquidity being the primary concern.
Our 12-month forecast assigns a 50% probability to a base case target range of $43–$49, a 30% probability to a bull case of $49–$53, and a 20% probability to a bear case of $22.30–$30. The base case assumes the merger closes with moderate synergies and forward EPS of $5.41 is met, while the bull case requires faster synergy realization and multiple expansion. The bear case hinges on merger failure or continued cash burn. The most likely scenario is the base case, with the key assumption being that working capital normalizes and free cash flow turns positive by late 2026.
INDV appears undervalued on forward earnings, trading at a forward PE of 7.14x versus a trailing PE of 21.36x, implying the market expects EPS to triple to $5.41. The PS ratio of 3.62x is also below its own recent history (12.05x in Q1 2026) and undemanding for a business with 80.1% gross margins. However, the discount is partly justified by negative free cash flow and merger uncertainty. If the forward EPS is achieved, the stock is significantly undervalued; if not, the low multiple reflects fair pricing. The market is pricing in substantial skepticism, so any positive surprise could trigger a re-rating.
From a risk/reward perspective, INDV offers 40.5% upside to the analyst average target of $49, but this is contingent on achieving the $5.41 forward EPS and resolving negative free cash flow of -$184.6 million. The stock trades at a forward PE of 7.14x, which is cheap if earnings materialize, but the current ratio of 0.71 and recent 10.66% one-month decline highlight near-term risks. It could be a good buy for investors with a high risk tolerance and a 12–18 month horizon who believe in the merger synergies and OUD franchise durability. However, those seeking stability or income (no dividend) should avoid it until cash flow turns positive.
INDV is better suited for medium-term (12–18 month) investment rather than short-term trading or long-term holding. The stock is event-driven, with the Supernus merger as a binary catalyst, and its beta of 1.113 and 21.37% max drawdown indicate meaningful volatility. There is no dividend (payout ratio 0), so returns depend entirely on capital appreciation. Earnings visibility is low given negative free cash flow and merger uncertainty, making it unsuitable for conservative long-term portfolios. A suggested minimum holding period is 12 months to allow for merger integration and cash flow improvement, but investors should be prepared to exit if the bear case materializes.